$36.05
0.72[2.04%]
At close: Apr 26
$36.05
0[0.00%]
After Hours: 5:49PM EDT
Revolution Medicines
(NASDAQ:RVMD)Revolution Medicines Stock (NASDAQ:RVMD), Analyst Ratings, Price Targets, Predictions
Revolution Medicines Inc has a consensus price target of $41.33, established from looking at the 47 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Needham, and Raymond James on April 12, 2024, April 12, 2024, and April 10, 2024. With an average price target of $46.33 between Oppenheimer, Needham, and Raymond James, there's an implied 28.53% upside for Revolution Medicines Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Needham
Raymond James
Piper Sandler
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Revolution Medicines
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | 24.83% | Oppenheimer | Jay Olson | $43 → $45 | Maintains | Outperform | Get Alert |
| 04/12/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | 27.6% | Needham | Ami Fadia | $36 → $46 | Maintains | Buy | Get Alert |
| 04/10/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | 33.15% | Raymond James | Laura Prendergast | $36 → $48 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/08/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | -0.14% | Needham | Ami Fadia | $36 → $36 | Maintains | Buy | Get Alert |
| 03/11/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | 19.28% | Piper Sandler | Joseph Catanzaro | → $43 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | 22.05% | HC Wainwright & Co. | Robert Burns | $28 → $44 | Maintains | Buy | Get Alert |
| 03/08/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | 96.95% | Morgan Stanley | — | $84 → $71 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | 16.5% | Wedbush | David Driscoll | $41 → $42 | Maintains | Outperform | Get Alert |
| 01/16/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | -0.14% | Raymond James | Laura Prendergast | $30 → $36 | Maintains | Outperform | Get Alert |
| 01/05/2024 | RVMD | Buy Now | Revolution Medicines | $36.05 | -5.69% | B of A Securities | Alec Stranahan | → $34 | Upgrade | Neutral → Buy | Get Alert |
| 12/20/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | 10.96% | UBS | Eliana Merle | → $40 | Initiates | → Buy | Get Alert |
| 11/16/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | -16.78% | Raymond James | Dane Leone | → $30 | Initiates | → Outperform | Get Alert |
| 11/13/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | -22.33% | HC Wainwright & Co. | Robert Burns | $32 → $28 | Maintains | Buy | Get Alert |
| 11/07/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | 8.18% | JP Morgan | Eric Joseph | $47 → $39 | Maintains | Overweight | Get Alert |
| 11/07/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | -0.14% | Needham | Ami Fadia | → $36 | Reiterates | Buy → Buy | Get Alert |
| 10/26/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | -11.23% | HC Wainwright & Co. | Robert Burns | → $32 | Reiterates | Buy → Buy | Get Alert |
| 10/23/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | 19.28% | Oppenheimer | Jay Olson | $40 → $43 | Maintains | Outperform | Get Alert |
| 10/23/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | -0.14% | Needham | Ami Fadia | $34 → $36 | Maintains | Buy | Get Alert |
| 10/12/2023 | RVMD | Buy Now | Revolution Medicines | $36.05 | -5.69% | Needham | Ami Fadia | → $34 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Revolution Medicines (RVMD)?
The latest price target for Revolution Medicines (NASDAQ: RVMD) was reported by Oppenheimer on April 12, 2024. The analyst firm set a price target for $45.00 expecting RVMD to rise to within 12 months (a possible 24.83% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Revolution Medicines (RVMD)?
The latest analyst rating for Revolution Medicines (NASDAQ: RVMD) was provided by Oppenheimer, and Revolution Medicines maintained their outperform rating.
When was the last upgrade for Revolution Medicines (RVMD)?
The last upgrade for Revolution Medicines Inc happened on April 10, 2024 when Raymond James raised their price target to $48. Raymond James previously had an outperform for Revolution Medicines Inc.
When was the last downgrade for Revolution Medicines (RVMD)?
The last downgrade for Revolution Medicines Inc happened on August 12, 2021 when Goldman Sachs changed their price target from $49 to $27 for Revolution Medicines Inc.
When is the next analyst rating going to be posted or updated for Revolution Medicines (RVMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revolution Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revolution Medicines was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating Revolution Medicines (RVMD) correct?
While ratings are subjective and will change, the latest Revolution Medicines (RVMD) rating was a maintained with a price target of $43.00 to $45.00. The current price Revolution Medicines (RVMD) is trading at is $36.05, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.